8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

(Amendment No. 1)

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2006

BIOANALYTICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Indiana	0-23357	35-1345024
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

2701 KENT AVENUE WEST LAFAYETTE, INDIANA	47906-1382
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (765) 463-4527

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act(17CFR240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act(17CFR240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act(17CFR240.13e-4(c))

Explanatory Note: This Amendment No. 1 amends the Current Report on Form 8-K of Bioanalytical Systems, Inc. (the "Company") dated May 10, 2006, reporting under Item 2.02 that the Registrant had issued a press release announcing results for the second quarter of fiscal year 2006 (the "Press Release"). This Amendment No. 1 amends the Current Report on Form 8-K dated May 10, 2006 in order to replace exhibit 99.1. As originally filed, exhibit 99.1 did not contain the Press Release, but contained portions of a press release that had been previously issued by the Company in 2005. The disclosure included under Item 2.02 of this Amendment No. 1 is the same as the disclosure included under Item 2.02 of the Current Report on Form 8-K dated May 10, 2006.

The information provided in Item 2.02 and Item 9.01 of this Form 8-K is being furnished and shall not be deemed "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 2.02 and Item 9.01 of this Form 8-K shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.

Item 2.02. Results of Operations and Financial Condition.

On May 10, 2006, Bioanalytical Systems, Inc. (the "Company") issued a press release announcing results for the second quarter of fiscal year 2006. The full text of the press release is furnished as exhibit 99.1 to this Form 8-K and is incorporated herein by reference.

Item 9.01.		Financial Statements and Exhibits.
	(a)	Not applicable.
	(b)	Not applicable.
	(c)	Exhibits
	99.1	Bioanalytical Systems, Inc. press release, issued May 10, 2006.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Bioanalytical Systems, Inc.
Date: May 17, 2006	By:  /s/  Michael R. Cox Michael R. Cox Vice President, Finance and Chief Financial Officer

Exhibit Index

Exhibit No. Description

99.1 Bioanalytical Systems, Inc. press release, issued May 10, 2006.

EX-99

Exhibit 99.1

FOR MORE INFORMATION:  Michael R. Cox

Phone   765.497.5829

mcox@bioanalytical.com

Bioanalytical Systems, Inc. Reports 36% Revenue Increase, Profit

for Second Quarter Fiscal 2006

WEST LAFAYETTE, Ind., May 10, 2006 —  Bioanalytical Systems, Inc. (Nasdaq:BASI) today reported financial results for its second fiscal quarter and six months ended March 31, 2006.

Revenue for the second fiscal quarter increased 36% to $12.4 million compared to $9.1 million for the second fiscal quarter of the prior year. The net income for the second fiscal quarter of 2006 was $538,000, or $0.11 per basic and diluted share, versus a net loss of $(896,000), or $(0.18) per basic and diluted share, for the second fiscal quarter of 2005. The gain in revenue was primarily the result of a 33% increase in service revenues. Over 50% of this increase in service revenues resulted from the delay of a significant laboratory contract in the first fiscal quarter of the current year, with the work being completed in the current fiscal quarter. Increased demand for the Company’s laboratory and toxicology services accounted for the remainder of the growth in service revenues. Product revenues increased 48%, returning to volumes experienced prior to fiscal 2005.

Cost of revenue for the current second quarter was $7.5 million, or 60% of revenue, compared to $6.7 million, or 74% of revenue in the same period last year. A portion of the increase in cost of revenue was the result of amortizing $145,000 of intangible costs related to 2003 acquisitions, as the Company changed its estimate of their useful lives. The net decrease in cost of revenue as a percentage of sales is the result of better utilization of the Company’s productive capacity.

General and administrative costs were $2.9 million for the quarter, an increase of $0.3 million over the second quarter of last year. This increase is attributable to increased administrative costs incurred in handling the higher volume of business and the expensing of stock options in the current year.

Revenue for the six months ended March 31, 2006 increased 19% to $22.3 million compared to $18.8 million for the similar period of the prior year. The net loss for the six months was $(178,000), or $(0.04) per basic and diluted share, versus a net loss of $(493,000), or $(0.10) per basic and diluted share, for the first six months of fiscal 2005. The increases in revenues were the result of a 19% increase in service revenues and a 17% increase in product revenues as a result of the same factors mentioned in the current quarter.

Cost of revenue for the current six months was $14.2 million, or 64% of revenue, compared to $12.8 million, or 68% of revenue in the same period last year. The higher margins experienced year-to-date is the result of higher capacity utilization compared to fiscal 2005.

The $1.2 million increase in general and administrative costs to a total of $5.8 million for the six months ended March 31, 2006 was the result of higher expenses in the Baltimore location, which was owned for a portion of the prior year but is being rented in the current year, coupled with the additional administrative demands created by a higher volume of services and product sales.

Peter T. Kissinger, Chairman and CEO said, “The cost cutting and refocusing announced early this year is just beginning to produce positive results for our shareholders. Nevertheless, I again caution that BASi is a research-driven business and quarterly results are not a reliable indicator at our present size. I am very pleased with the re-energized teams at all five laboratory sites, now united by our improved corporate IT infrastructure which has been long in coming.”

Bioanalytical Systems, Inc. is a pharmaceutical development company providing contract research services and monitoring instruments to the world’s leading drug development companies. BASi focuses on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market. Visit www.bioanalytical.com for more about BASi.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company’s filings with the Securities and Exchange Commission.

SEE ATTACHMENT FOR CONSOLIDATED STATEMENTS OF OPERATIONS

Bioanalytical Systems, Inc.

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share amounts)

(Unaudited)

	Three Months Ended March 31,						Six Months Ended March 31,
	2006			2005			2006			2005
Service revenue	$	10,053		$	7,543		$	17,592		$	14,832
Product revenue		2,364			1,596			4,669			4,001
Total revenue		12,417			9,139			22,261			18,833
Cost of service revenue		6,758			6,056			12,622			11,271
Cost of product revenue		725			657			1,560			1,509
Total cost of revenue		7,483			6,713			14,182			12,780
Gross profit		4,934			2,426			8,079			6,053
Operating expenses:
Selling		680			626			1,413			1,202
Research and development		201			173			639			392
General and administrative		2,886			2,615			5,771			4,542
Total operating expenses		3,767			3,414			7,823			6,136
Operating income (loss)		1,167			(988	)		256			(83	)
Interest income		2			2			4			4
Interest expense		(249	)		(257	)		(508	)		(532	)
Other expense		——			(28	)		——			(22	)
Income (loss) before income taxes		921			(1,271	)		(248	)		(633	)
Income taxes		383			(375	)		(70	)		(140	)
Net income (loss)	$	538		$	(896	)	$	(178	)	$	(493	)
Net income (loss) per share:
Basic	$	0.11		$	(0.18	)	$	(0.04	)	$	(0.10	)
Diluted	$	0.11		$	(0.18	)	$	(0.04	)	$	(0.10	)
Weighted common and common equivalent
shares outstanding:
Basic		4,875			4,870			4,873			4,870
Diluted		4,971			4,870			4,873			4,870